Tag: mumps vaccine market analysis

  • Mumps Vaccine (MumpsVax) Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead

    Discover trends, market shifts, and competitive outlooks for the mumps vaccine (mumpsvax) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    What Is the Current and Projected Market Size of the Mumps Vaccine (MumpsVax) Market Through 2034?

    In recent times, the mumps vaccine (mumpsvax) sector has significantly expanded, projecting a growth from $2,057.93 million in 2024 to $2,210.59 million in 2025, yielding a compound annual growth rate (CAGR) of 7.4%. Such growth during the historic period can be associated with factors like an increase in child vaccine rates, rise in global health initiatives, a growth in public reliance on vaccines, improved travel awareness, and an upsurge in immunization drives.

    Anticipated robust augmentation is seen in the mumps vaccine (mumpsvax) market size in the forthcoming years. Projected to inflate to $2,902.21 million by 2029, it carries a compound annual growth rate (CAGR) of 7.0%. This upswing during the prophesied period can be associated with escalating cases of diseases that can be prevented through vaccination, heightened awareness about adult vaccination, increasing health-conscious populace, expansion of immunization programs, and growth of global health initiatives. Key trends in the predicted timeline encompass personalized immunization tactics, incorporation of digital health, improved surveillance systems, research and development in the realm of adult vaccination, and integration of artificial intelligence in the field.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=19909&type=smp

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Mumps Vaccine (MumpsVax) Market?

    The increased occurrence of infectious diseases is projected to drive the growth of the mumps vaccine (mumpsvax) market. These diseases are triggered by harmful microorganisms like viruses, bacteria, fungi, or parasites that can spread from person to person or via polluted surroundings. The factors contributing to this increase include urbanization, climate change, globalization, altered human demographics, and behaviors that enable the outbreak of pathogens. Mumpsvax, a vaccine for mumps, is primarily utilized to thwart mumps infection, a disease spread by the mumps virus. Typically, it is part of the MMR (measles, mumps, rubella) immunization. For example, a report by the UK Health Security Agency in August 2024 revealed that in 2023, the West Midlands region reported the most measles cases, counting for 160 cases (44%), followed by London with 122 cases (33%). Importantly children under 10 constituted 63% of the total cases, equivalent to 232 cases. As the year ended there was a substantial spike in measles activity, recording 157 new cases in December as opposed to just 45 cases in November. Consequently, the escalating prevalence of infectious diseases bolsters the mumps vaccine (mumpsvax) market. A surge in healthcare expenditure is projected to drive the mumps vaccine (mumpsvax) market by promoting access to Mumpsvax and boosting immunization rates. This expenditure encompasses the total amount spent on healthcare items and services including personal care, preventive services and public health measures, all with the aim to improve health outcomes within a specific timeframe. The driving forces behind the increasing healthcare expenditure include an aging populace, chronic illnesses, sophisticated medical equipment, high drug prices, ineffective payment systems, and an augmented demand for services. This rising expenditure influences the mumps vaccine (mumpsvax) market by fortifying funding for vaccination initiatives, thus enhancing reach of the vaccine and subsequently promoting improved public health results through increased immunization coverage against mumps. For example, a report by the Office For National Statistics in May 2024 revealed that the total healthcare expenditure saw a 5.6% rise in nominal terms from 2022 to 2023 compared to a growth of 0.9% in 2022. Furthermore, overall long-term health and social expenditure saw an increase of 2.8% in real terms in 2022. As a result, this growth in healthcare expenditure plays a significant role in advancing the mumps vaccine (mumpsvax) market.

    Which Key Market Segments Comprise the Mumps Vaccine (MumpsVax) Market and Drive Its Revenue Growth?

    The mumps vaccine (mumpsvax)market covered in this report is segmented –

    1) By Product Type: Monovalent; Combinational; Divalent; Trivalent; Other Product Types

    2) By Age Group: Pediatric; Adult

    3) By Distribution Channels: Hospital pharmacies; Drug Stores; Retail Pharmacies

    4) By End-User: Pediatric Clinic; Hospitals; Non-Governmental Organization (NGOs); Other End-Users

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=19909&type=smp

    Which Areas Are Leading Regions in the Mumps Vaccine (MumpsVax) Market Expansion Across the Globe?

    North America was the largest region in the mumps vaccine (mumpsvax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mumps vaccine (mumpsvax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/mumps-vaccine-mumpsvax-global-market-report

    How Is the Mumps Vaccine (MumpsVax) Market Conceptually Defined?

    Mumps vaccine (MumpsVax) is a live attenuated vaccine that prevents mumps using the Jeryl Lynn strain of the virus. Administered in two doses, it is often combined with the MMR (measles, mumps, rubella) vaccine and provides over 95% protection against mumps. Although standalone production has ceased, mumps vaccine (mumpsvax) remains crucial for public health efforts to reduce mumps outbreaks and has significantly lowered incidence rates in vaccinated populations.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19909

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Mumps Vaccine (MumpsVax) Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

    Mumps Vaccine (MumpsVax) Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Mumps Vaccine (MumpsVax) Market?

    The escalating occurrence of infectious diseases is anticipated to boost the expansion of the mumps vaccine (mumpsvax) market. Illnesses prompted by infectious agents like viruses, bacteria, fungi, or parasites that can be transferred from human to human or via polluted environments define infectious diseases. The surge in infectious diseases can be attributed to factors like urbanization, climate alteration, globalization and changes in human demographics and behaviors, escalating the emergence and transmission of pathogens. Mumpsvax, a vaccine used primarily to avert mumps infection, exists as an infectious disease triggered by the mumps virus and is frequently included in the MMR (measles, mumps, rubella) vaccination. For example, a UK Health Security Agency report in August 2024 indicated that the West Midlands region had reported the most measles cases in 2023, with 160 cases (44%), followed by London with 122 cases (33%). Interestingly, children below ten years old accounted for 63% of the total cases, equating to 232 cases. The end of the year saw an upsurge in measles activity, with 157 new instances recorded in December as opposed to just 45 in November. Thus, the elevated prevalence of infectious diseases is fuelling the mumps vaccine (mumpsvax) market. Acceleration in healthcare expenditure is projected to boost the mumps vaccine (mumpsvax) market by enhancing mumpsvax access and immunization rates. The term healthcare expenditure encompasses the aggregate sum spent on health care goods and services, inclusive of personal healthcare, preventive actions, and public health activities, with the end goal of ameliorating health outcomes within a specific timespan. The increment in healthcare expenditure can be ascribed to factors like an aging populace, chronic diseases, advanced medical tech, high drug cost, inefficient payment systems, and augmented demand for services. The rise in healthcare expenditure impacts the mumps vaccine (mumpsvax) by elevating funding for vaccination initiatives, thereby improving vaccine accessibility and promoting better public health outcomes via escalated immunization rates against mumps. A report by the Office For National Statistics in May 2024 emphasized that between 2022 to 2023, total healthcare expenditure rose by 5.6% in nominal terms, compared to a growth rate of 0.9% in 2022. Total healthcare and social care expenditure for the long term also rose by 2.8% in real terms in 2022. Thus, increasing healthcare expenditure is fuelling the mumps vaccine (mumpsvax) market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=19909&type=smp

    #What Growth Opportunities Will Drive the Mumps Vaccine (MumpsVax) Market’s CAGR Through 2034?

    The mumps vaccine (mumpsvax) market has expanded steadily. It is expected to increase from $2,057.93 million in 2024 to $2,210.59 million in 2025 at a 7.4% CAGR. Drivers include rising childhood immunization rates, global health campaigns, growing trust in vaccines, travel awareness, and more immunization programs.

    The Mumps Vaccine (Mumpsvax) market is forecasted to expand, growing to $2,902.21 million by 2029 with a CAGR of 7.0%. Growth factors include the resurgence of vaccine-preventable diseases, improved public awareness of adult immunization, increasing health consciousness, government-backed immunization drives, and strengthened global health initiatives. Emerging trends involve tailored vaccination plans, integration of digital health tools, improved disease surveillance, intensified R&D in adult vaccines, and the application of AI in vaccine strategy.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19909

    Who Are the Top Companies Driving Innovation and Growth in theMumps Vaccine (MumpsVax) Market?

    Major companies operating in the mumps vaccine (mumpsvax) market include Merck & Co. Inc., GlaxoSmithKline plc

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/mumps-vaccine-mumpsvax-global-market-report

    Which Key Market Segments Comprise the Mumps Vaccine (MumpsVax) Market and Drive Its Revenue Growth?

    The mumps vaccine (mumpsvax)market covered in this report is segmented –

    1) By Product Type: Monovalent; Combinational; Divalent; Trivalent; Other Product Types

    2) By Age Group: Pediatric; Adult

    3) By Distribution Channels: Hospital pharmacies; Drug Stores; Retail Pharmacies

    4) By End-User: Pediatric Clinic; Hospitals; Non-Governmental Organization (NGOs); Other End-Users

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=19909&type=smp

    Which Regions Are Emerging as Leaders in the Mumps Vaccine (MumpsVax) Market?

    North America was the largest region in the mumps vaccine (mumpsvax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mumps vaccine (mumpsvax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Mumps Vaccine (MumpsVax) Market 2025, By The Business Research Company:

    Dendritic Cell Cancer Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/dendritic-cell-cancer-vaccine-global-market-report

    Porcine Epidemic Diarrhea Vaccines Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

    Global Biosimilar Hormones Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Mumps Vaccine (MumpsVax) Market Forecast and Analysis: Key Insights into Growth, Trends, and Emerging Opportunities

    Mumps Vaccine (MumpsVax) Market Forecast and Analysis: Key Insights into Growth, Trends, and Emerging Opportunities

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How Will the Growth Rate of the Mumps Vaccine (MumpsVax) Market Shape Industry Trends by 2034?

    The market for the mumps vaccine (mumpsvax) has witnessed robust growth in the past few years. It is projected to expand from a value of $2,057.93 million in 2024 to $2,210.59 million in 2025, reflecting a compound annual growth rate (CAGR) of 7.4%. Various factors have driven the growth during the historic period, including the rise in pediatric vaccination rates, proliferation of global health initiatives, growing public confidence in vaccines, heightened travel awareness and expanded immunization campaigns.

    In the upcoming years, a significant surge is expected in the mumps vaccine (mumpsvax) market, projecting to escalate to $2,902.21 million by 2029, with a compound annual growth rate (CAGR) of 7.0%. The speculated growth during the forecast period can be ascribed to the escalating occurrence of diseases that can be prevented by vaccines, increased awareness regarding adult vaccinations, heightened health consciousness, expansion of immunization programs, and the rise of global health initiatives. Key trends for the forecast period encompass customized vaccination approaches, incorporation of digital health, improved surveillance systems, research and development in adult vaccination, and the integration of artificial intelligence.

    Which Primary Drivers Are Supporting the Continued Expansion of the Mumps Vaccine (MumpsVax) Market?

    The rise in contagious illnesses is set to catalyze the growth of the MumpsVax market. These diseases manifest due to harmful microbes, such as fungi, bacteria, viruses, or parasites, which can be spread from person to person or from contact with polluted environments. The surge in such diseases is largely fueled by factors like globalisation, climate change, urbanisation, and shifts in human demographics and behavior, which facilitate the spread and emergence of pathogens. MumpsVax, a vaccine for mumps, is primarily utilized to prevent an infection caused by the mumps virus, usually included in the MMR (measles, mumps, rubella) vaccine. For example, in August 2024, a report from the UK Health Security Agency indicated that, in 2023, West Midlands region registered the highest number of measles incidents, with 160 cases (44%), followed by London’s 122 cases (33%). Noteworthy is that 63% of the entire cases, equalling to 232 cases, were children under 10. Measles surged dramatically towards the year’s close, with 157 fresh cases documented in December, in contrast to only 45 in November. Therefore, the increasing prevalence of contagious diseases is fueling the MumpsVax market.

    Explore Comprehensive Insights Into The Global Mumps Vaccine (MumpsVax) Market With A Free Sample Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=19909&type=smp

    Who Are the Key Market Players Influencing the Growth of the Mumps Vaccine (MumpsVax) Industry?

    Major companies operating in the mumps vaccine (mumpsvax) market include Merck & Co. Inc., GlaxoSmithKline plc

    Secure Your Global Mumps Vaccine (MumpsVax) Market Report Now for Fast and Efficient Delivery!

    https://www.thebusinessresearchcompany.com/report/mumps-vaccine-mumpsvax-global-market-report

    What Are the Main Segments of the Mumps Vaccine (MumpsVax) Market, and How Are They Evolving?

    The mumps vaccine (mumpsvax)market covered in this report is segmented –

    1) By Product Type: Monovalent; Combinational; Divalent; Trivalent; Other Product Types

    2) By Age Group: Pediatric; Adult

    3) By Distribution Channels: Hospital pharmacies; Drug Stores; Retail Pharmacies

    4) By End-User: Pediatric Clinic; Hospitals; Non-Governmental Organization (NGOs); Other End-Users

    Which Regions Are Emerging as Leaders in the Mumps Vaccine (MumpsVax) Market?

    North America was the largest region in the mumps vaccine (mumpsvax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mumps vaccine (mumpsvax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Defining Features of the Mumps Vaccine (MumpsVax) Market?

    Mumps vaccine (MumpsVax) is a live attenuated vaccine that prevents mumps using the Jeryl Lynn strain of the virus. Administered in two doses, it is often combined with the MMR (measles, mumps, rubella) vaccine and provides over 95% protection against mumps. Although standalone production has ceased, mumps vaccine (mumpsvax) remains crucial for public health efforts to reduce mumps outbreaks and has significantly lowered incidence rates in vaccinated populations.

    Browse Through More Similar Reports By The Business Research Company:

    Dendritic Cell Cancer Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/dendritic-cell-cancer-vaccine-global-market-report

    Porcine Epidemic Diarrhea Vaccines Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

    Global Biosimilar Hormones Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: